CL2017002718A1 - Peptido teniendo efectos contra la obesidad y la diabetes y sus usos asociados - Google Patents

Peptido teniendo efectos contra la obesidad y la diabetes y sus usos asociados

Info

Publication number
CL2017002718A1
CL2017002718A1 CL2017002718A CL2017002718A CL2017002718A1 CL 2017002718 A1 CL2017002718 A1 CL 2017002718A1 CL 2017002718 A CL2017002718 A CL 2017002718A CL 2017002718 A CL2017002718 A CL 2017002718A CL 2017002718 A1 CL2017002718 A1 CL 2017002718A1
Authority
CL
Chile
Prior art keywords
diabetes
peptide
effects against
against obesity
associated uses
Prior art date
Application number
CL2017002718A
Other languages
English (en)
Inventor
Yong Ji Chung
Eun Mi Klm
Original Assignee
Caregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caregen Co Ltd filed Critical Caregen Co Ltd
Publication of CL2017002718A1 publication Critical patent/CL2017002718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2017002718A 2015-04-28 2017-10-26 Peptido teniendo efectos contra la obesidad y la diabetes y sus usos asociados CL2017002718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150059648A KR101669140B1 (ko) 2015-04-28 2015-04-28 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도

Publications (1)

Publication Number Publication Date
CL2017002718A1 true CL2017002718A1 (es) 2018-11-09

Family

ID=57198486

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2017002718A CL2017002718A1 (es) 2015-04-28 2017-10-26 Peptido teniendo efectos contra la obesidad y la diabetes y sus usos asociados
CL2019002960A CL2019002960A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718)
CL2019002958A CL2019002958A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718)
CL2019002959A CL2019002959A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718).

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2019002960A CL2019002960A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718)
CL2019002958A CL2019002958A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718)
CL2019002959A CL2019002959A1 (es) 2015-04-28 2019-10-17 Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718).

Country Status (21)

Country Link
US (4) US10351597B2 (es)
EP (4) EP3613758B1 (es)
JP (4) JP6606192B2 (es)
KR (1) KR101669140B1 (es)
CN (3) CN106459152B (es)
AU (4) AU2015393357B2 (es)
BR (4) BR122020019095B1 (es)
CA (4) CA3074836C (es)
CL (4) CL2017002718A1 (es)
CO (1) CO2017011998A2 (es)
EA (1) EA037799B1 (es)
ES (4) ES2895167T3 (es)
IL (4) IL255263B (es)
MX (4) MX381975B (es)
MY (4) MY197887A (es)
NZ (4) NZ747396A (es)
PH (1) PH12017501983A1 (es)
SA (4) SA520420880B1 (es)
SG (4) SG10201913490WA (es)
WO (1) WO2016175362A1 (es)
ZA (1) ZA201708044B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR101887576B1 (ko) 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR101955511B1 (ko) * 2016-08-17 2019-03-11 (주)진셀팜 지방분해 촉진 효과를 가지는 펩타이드, 및 이의 용도
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102386705B1 (ko) * 2016-11-07 2022-04-21 주식회사 삼양사 알룰로스의 항비만 활성 관련 마커 유전자 및 이의 용도
CN106518971B (zh) * 2016-12-05 2019-12-10 华南理工大学 一种抗肥胖十肽canphelpnk
CN106699846B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖十一肽nalkcchscpa
CN106749524B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖七肽npvwkrk
CN106749533B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖十七肽lnnpsvcdcdcmmkaar
JP7133982B2 (ja) * 2017-08-10 2022-09-09 小林製薬株式会社 錠剤組成物
KR101920047B1 (ko) 2018-01-03 2018-11-19 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
KR102171141B1 (ko) * 2018-05-28 2020-10-28 중앙대학교 산학협력단 Lgi3 유래 펩타이드를 유효성분으로 포함하는 비만의 예방, 치료, 또는 개선용 조성물
CN109081862A (zh) * 2018-06-07 2018-12-25 华南理工大学 一种抗肥胖四肽pqtr及其应用
CN108676073B (zh) * 2018-06-07 2021-10-26 华南理工大学 一种抗肥胖十肽llvvypwtqr及其应用
CN112010941B (zh) * 2019-05-31 2022-08-16 华南理工大学 一种降血糖七肽
CN113248628B (zh) * 2021-07-13 2021-10-22 南京市妇幼保健院 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
KR102736938B1 (ko) * 2021-09-30 2024-12-03 (주)케어젠 항비만 활성을 갖는 펩타이드 및 이의 용도
TWI864612B (zh) * 2022-03-24 2024-12-01 南韓商凱爾格恩有限公司 具有抗肥胖與抗糖尿病活性的胜肽、包含其之醫藥組成物及包含其之機能性食品組成物
KR102816262B1 (ko) * 2022-04-18 2025-06-05 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도
KR102816261B1 (ko) * 2022-03-24 2025-06-05 (주)케어젠 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도
KR20240133923A (ko) * 2023-02-28 2024-09-05 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR102907151B1 (ko) * 2023-07-27 2026-01-06 (주)케어젠 펩타이드 복합물을 유효성분으로 포함하는 피부 상태 개선용 조성물
CN118791560B (zh) * 2024-06-17 2025-02-25 广州慕可生物科技有限公司 一种具有调理皮脂分泌的肽类及其合成方法与应用
CN119080877B (zh) * 2024-10-11 2025-09-23 完美（广东）日用品有限公司 一种低聚肽及其在制备减脂制品中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
DE69740176D1 (de) * 1996-03-01 2011-05-26 Novo Nordisk As Appetithemmendes Peptid, Zusammensetzung und Verwendung
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20020132767A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1255774B1 (en) * 2000-02-18 2005-09-14 LeanGene AB Methods for identifying compounds useful for the treatment of obesity involving foxc2
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
CA2388287A1 (en) * 2001-05-30 2002-11-30 Terry E. Graham Therapies for the prevention and treatment of diabetes and obesity
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2473781A1 (en) 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US20050143297A1 (en) 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
CN1980686A (zh) * 2004-04-05 2007-06-13 安斯泰来制药有限公司 抗肥胖药
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
CN101415461A (zh) * 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
EP1989226A4 (en) * 2006-03-06 2009-11-18 Caregen Co Ltd PEPTIDES HAVING INSULIN-TYPE GROWTH FACTOR ACTIVITY 1 AND USES THEREOF
KR101459789B1 (ko) * 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
CN101091765A (zh) * 2007-06-08 2007-12-26 余仁生国际有限公司 药物组合物及其预防和治疗糖尿病的用途
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
ES2538694T3 (es) * 2011-04-01 2015-06-23 F. Hoffmann-La Roche Ag Variantes de la T7 ARN polimerasa con sustituciones de Cisteína-Serina
KR101363455B1 (ko) * 2011-09-09 2014-02-21 (주)케어젠 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
KR20140027594A (ko) 2012-07-23 2014-03-07 씨지케이바이오 주식회사 항당뇨 및 항비만 활성을 갖는 약학 조성물
ES2704280T3 (es) 2012-09-21 2019-03-15 Dow Global Technologies Llc Método para tratar tejidos con un agente fijador de tinte
EP3395358B1 (en) * 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
KR101510742B1 (ko) 2013-05-13 2015-04-10 (주)케어젠 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도
US10471125B2 (en) 2014-03-13 2019-11-12 Universite Grenoble Alpes Pharmaceutical compositions and their use for the treatment of autoimmune disorders
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CA3074836C (en) 2021-06-15
ES2831329T3 (es) 2021-06-08
KR101669140B1 (ko) 2016-10-26
SG10201913487RA (en) 2020-02-27
BR122020019171B1 (pt) 2023-11-07
AU2015393357B2 (en) 2019-05-16
EP3290434A4 (en) 2018-08-15
CN110105432B (zh) 2022-12-27
JP6813156B2 (ja) 2021-01-13
ES2894638T3 (es) 2022-02-15
AU2019203655B2 (en) 2020-07-02
EP3290434A1 (en) 2018-03-07
IL282513A (en) 2021-06-30
SG10201913489UA (en) 2020-02-27
CA3074800A1 (en) 2016-11-03
CA3074790C (en) 2023-01-31
AU2019203659B2 (en) 2020-07-02
JP2020007372A (ja) 2020-01-16
EP3290434B1 (en) 2020-08-19
MY197886A (en) 2023-07-23
MX381975B (es) 2025-03-13
MY192154A (en) 2022-08-02
CN110172083B (zh) 2022-12-30
CN110172083A (zh) 2019-08-27
CN110105432A (zh) 2019-08-09
NZ747390A (en) 2020-08-28
EA201792365A1 (ru) 2018-04-30
NZ747392A (en) 2020-08-28
AU2019203655A1 (en) 2019-06-13
MX2020012993A (es) 2022-10-13
EA037799B1 (ru) 2021-05-21
IL282513B (en) 2022-01-01
ES2893468T3 (es) 2022-02-09
EP3613760A1 (en) 2020-02-26
JP6908085B2 (ja) 2021-07-21
CL2019002960A1 (es) 2020-02-21
SG10201913490WA (en) 2020-03-30
ZA201708044B (en) 2022-09-28
CO2017011998A2 (es) 2018-02-09
EP3613758B1 (en) 2021-07-21
CL2019002959A1 (es) 2020-02-21
US10626145B2 (en) 2020-04-21
EP3613759B1 (en) 2021-07-21
IL282510A (en) 2021-06-30
MX2017013847A (es) 2018-06-15
IL282514A (en) 2021-06-30
CL2019002958A1 (es) 2020-02-21
CN106459152A (zh) 2017-02-22
BR112017023199B1 (pt) 2023-11-07
US20190270773A1 (en) 2019-09-05
MX2020012992A (es) 2022-10-13
US20190270774A1 (en) 2019-09-05
CA2984287C (en) 2021-01-19
BR122020019095B1 (pt) 2023-11-14
AU2019203657B2 (en) 2020-07-02
SA520420882B1 (ar) 2021-11-14
CA2984287A1 (en) 2016-11-03
JP2020007371A (ja) 2020-01-16
SG11201708847VA (en) 2017-11-29
JP6606192B2 (ja) 2019-11-13
JP6813155B2 (ja) 2021-01-13
EP3613758A1 (en) 2020-02-26
CA3074790A1 (en) 2016-11-03
US20190270772A1 (en) 2019-09-05
IL255263A (en) 2018-04-30
US11186611B2 (en) 2021-11-30
SA520420880B1 (ar) 2021-11-14
EP3613760B1 (en) 2021-07-28
ES2895167T3 (es) 2022-02-17
HK1252251A1 (en) 2019-05-24
CA3074800C (en) 2022-04-12
MX2020012994A (es) 2022-10-13
CN106459152B (zh) 2019-06-28
IL255263B (en) 2022-02-01
IL282514B (en) 2022-01-01
MY197888A (en) 2023-07-23
BR112017023199A2 (pt) 2019-01-29
CA3074836A1 (en) 2016-11-03
PH12017501983B1 (en) 2018-03-19
EP3613759A1 (en) 2020-02-26
AU2015393357A1 (en) 2017-11-30
NZ737077A (en) 2019-05-31
WO2016175362A1 (ko) 2016-11-03
MY197887A (en) 2023-07-23
AU2019203659A1 (en) 2019-06-13
SA517390237B1 (ar) 2021-03-17
AU2019203657A1 (en) 2019-06-13
NZ747396A (en) 2020-10-30
US10351597B2 (en) 2019-07-16
IL282510B (en) 2022-01-01
US20180118783A1 (en) 2018-05-03
PH12017501983A1 (en) 2018-03-19
BR122020019077B1 (pt) 2023-11-07
SA520420881B1 (ar) 2023-01-15
US10738081B2 (en) 2020-08-11
JP2020007373A (ja) 2020-01-16
JP2018515471A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
CL2017002718A1 (es) Peptido teniendo efectos contra la obesidad y la diabetes y sus usos asociados
IL285286A (en) Transposase polypeptides and uses thereof
IL293377A (en) Hsd17b13 variants and uses thereof
IL268593A (en) Polypeptide variants and uses thereof
CL2016002733A1 (es) Combinación de lenalidomida y constructo de polipéptido, y sus usos
EP3411494A4 (en) HIGH-RESOLUTION SEQUENCING
PL3314343T3 (pl) Osobiste drony sensoryczne
DK3778595T3 (da) Pancreatitisbehandling
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3245331T3 (da) Fortøjningselement
DK3334576T3 (da) Stavelement
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3316951T3 (da) Eyewear and flexible elements
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
IL271073A (en) B4galt1 variants and uses thereof
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
MA43533A (fr) Élément de récipient sous pression à construction en duplex
DK3250234T3 (da) Rekombinant mdv1 og anvendelser deraf
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
EP3358833A4 (en) Head-mounted display
BR112017018932A2 (pt) etv2 e usos do mesmo
ES1137060Y (es) Clip para el cabello